孟鲁司特钠与沙美特罗替卡松粉吸入剂联合治疗支气管哮喘临床疗效探讨
|
摘要
目的探讨孟鲁司特钠与沙美特罗替卡松粉吸入剂联合治疗支气管哮喘临床疗效。方法方便选取该院2017年6月—2018年6月该院收治的88例支气管哮喘,随机分为两组:对照组44例给予沙美特罗替卡松粉吸入剂治疗,观察组44例给予孟鲁司特钠与沙美特罗替卡松粉吸入剂联合治疗,比较两组临床疗效、治疗前后肺功能指标、炎性因子指标和免疫功能指标改善情况。结果观察组治疗总有效率为95.45%,显著高于对照组的79.55%(χ~2=11.557,P<0.05);观察组治疗后的FVC、PEF、FEV1水平分别为(2.56±0.30)L/s、(4.90±0.79)L/s、(2.36±0.22))L/s,均显著高于对照组(t=3.780、2.389、13.740,P<0.05);观察组治疗后的IL-6和TNF-α水平均分别为(0.16±0.06)ng/L、(435.67±72.09)ng/L,均显著低于对照组(t=5.945、25.482,P<0.05);观察组治疗后的血清CD4+、CD8+、CD4+/CD8+水平分别为(38.36±3.69)%、(28.85±2.55)%、(1.56±0.43)%,均显著高于对照组(t=4.292、5.211、2.235,P<0.05)。结论对于支气管哮喘患者,给予孟鲁司特钠与沙美特罗替卡松粉吸入剂联合治疗效果确切,可显著改善患者肺功能,提高患者免疫功能和改善肺功能,下调炎性因子水平。
Objective To investigate the clinical efficacy of montelukast sodium combined with salmeterol and ticasone powder inhalation in the treatment of bronchial asthma. Methods 88 patients with bronchial asthma admitted to our hospital from June 2017 to June 2018 were randomly divided into two groups: 44 patients in the control group were treated with salmeterol and sedatives, and 44 patients in the observation group with the combination of lust sodium and salmeterol and ticasone powder inhalation, to compare the clinical efficacy, lung function index, inflammatory factor index and immune function index before and after treatment. Results The total effective rate of the observation group was 95.45%, which was significantly higher than that of the control group 79.55%(χ~2=11.557, P<0.05). The levels of FVC, PEF and FEV1 in the observation group were(2.56±0.30) L/s,(4.90±0.79) L/s,(2.36±0.22) L/s, which were significantly higher than the control group(t=3.780, 2.389, 13.740, P<0.05); IL-6 and TNF after treatment in the observation group mean α-α was(0.16±0.06)ng/L and(435.67±72.09) ng/L, which were significantly lower than the control group(t=5.945, 25.482, P<0.05). The serum CD4+of the observation group after treatment. The levels of CD8+and CD4+/CD8+were(38.36±3.69)%,(28.85±2.55)%, and(1.56±0.43)%, respectively, which were significantly higher than the control group(t=4.292, 5.211,2.235, P<0.05). Conclusion For patients with bronchial asthma, the combination of montelukast sodium and salmeterol fluticasone powder inhalation is effective, which can significantly improve lung function, improve immune function, and down-regulate inflammatory factors.
Objective To investigate the clinical efficacy of montelukast sodium combined with salmeterol and ticasone powder inhalation in the treatment of bronchial asthma. Methods 88 patients with bronchial asthma admitted to our hospital from June 2017 to June 2018 were randomly divided into two groups: 44 patients in the control group were treated with salmeterol and sedatives, and 44 patients in the observation group with the combination of lust sodium and salmeterol and ticasone powder inhalation, to compare the clinical efficacy, lung function index, inflammatory factor index and immune function index before and after treatment. Results The total effective rate of the observation group was 95.45%, which was significantly higher than that of the control group 79.55%(χ~2=11.557, P<0.05). The levels of FVC, PEF and FEV1 in the observation group were(2.56±0.30) L/s,(4.90±0.79) L/s,(2.36±0.22) L/s, which were significantly higher than the control group(t=3.780, 2.389, 13.740, P<0.05); IL-6 and TNF after treatment in the observation group mean α-α was(0.16±0.06)ng/L and(435.67±72.09) ng/L, which were significantly lower than the control group(t=5.945, 25.482, P<0.05). The serum CD4+of the observation group after treatment. The levels of CD8+and CD4+/CD8+were(38.36±3.69)%,(28.85±2.55)%, and(1.56±0.43)%, respectively, which were significantly higher than the control group(t=4.292, 5.211,2.235, P<0.05). Conclusion For patients with bronchial asthma, the combination of montelukast sodium and salmeterol fluticasone powder inhalation is effective, which can significantly improve lung function, improve immune function, and down-regulate inflammatory factors.
引文
[1]王秀亮,马玉.支气管哮喘采用孟鲁司特钠联合布地奈德治疗临床疗效分析[J].中外医疗,2017,36(33):115-116,119.
[2]彭惠忠.沙美特罗替卡松粉吸入剂结合孟鲁司特钠治疗支气管哮喘患者的临床效果观察[J].现代实用医学,2017,29(8):1046-1048.
[3]邢学伟,葛昌玲.沙美特罗联合孟鲁司特钠对小儿支气管哮喘肺功能及TNF-α、NO、ET表达的影响[J].广西医科大学学报,2017,34(8):1185-1188.
[4]李浩,付爱国,贾瑷阁.孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘的疗效观察[J].中国医院用药评价与分析,2018,18(5):608-609,612.
[5]吕明明.白三烯受体拮抗剂联合沙美特罗替卡松治疗老年支气管哮喘患者的临床疗效[J].中国药物经济学,2016,11(12):41-43.
[6]王培养.孟鲁司特钠联合沙美特罗替卡松治疗小儿支气管哮喘急性发作临床效果及对免疫因子的影响[J].中国妇幼保健,2016,31(22):4758-4760.
[7]许顺贵,季康.孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗咳嗽变异性哮喘的临床观察[J].中国药房,2015,26(12):1610-1611.
[8]冯永刚,席建轲.孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床研究[J].中国医药导刊,2017,19(7):731-733.
[9]何会,李荆萍.孟鲁司特钠片与沙美特罗替卡松粉吸入剂联用对哮喘患者的临床疗效评价[J].抗感染药学,2016,13(2):380-382.
[10]陈昌彪.沙美特罗替卡松粉吸入剂联合孟鲁司特钠治疗支气管哮喘70例疗效分析[J].临床合理用药杂志,2014,7(11):46-47.
[11]姜增凯,贾萍,叶晓歌.孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床疗效及其对炎性因子、肺功能、免疫功能的影响研究[J].实用心脑肺血管病杂志,2016,24(4):49-52.
[2]彭惠忠.沙美特罗替卡松粉吸入剂结合孟鲁司特钠治疗支气管哮喘患者的临床效果观察[J].现代实用医学,2017,29(8):1046-1048.
[3]邢学伟,葛昌玲.沙美特罗联合孟鲁司特钠对小儿支气管哮喘肺功能及TNF-α、NO、ET表达的影响[J].广西医科大学学报,2017,34(8):1185-1188.
[4]李浩,付爱国,贾瑷阁.孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗哮喘的疗效观察[J].中国医院用药评价与分析,2018,18(5):608-609,612.
[5]吕明明.白三烯受体拮抗剂联合沙美特罗替卡松治疗老年支气管哮喘患者的临床疗效[J].中国药物经济学,2016,11(12):41-43.
[6]王培养.孟鲁司特钠联合沙美特罗替卡松治疗小儿支气管哮喘急性发作临床效果及对免疫因子的影响[J].中国妇幼保健,2016,31(22):4758-4760.
[7]许顺贵,季康.孟鲁司特钠片联合沙美特罗替卡松粉吸入剂治疗咳嗽变异性哮喘的临床观察[J].中国药房,2015,26(12):1610-1611.
[8]冯永刚,席建轲.孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床研究[J].中国医药导刊,2017,19(7):731-733.
[9]何会,李荆萍.孟鲁司特钠片与沙美特罗替卡松粉吸入剂联用对哮喘患者的临床疗效评价[J].抗感染药学,2016,13(2):380-382.
[10]陈昌彪.沙美特罗替卡松粉吸入剂联合孟鲁司特钠治疗支气管哮喘70例疗效分析[J].临床合理用药杂志,2014,7(11):46-47.
[11]姜增凯,贾萍,叶晓歌.孟鲁司特钠联合沙美特罗替卡松粉吸入剂治疗支气管哮喘的临床疗效及其对炎性因子、肺功能、免疫功能的影响研究[J].实用心脑肺血管病杂志,2016,24(4):49-52.